BCL2 and mantle cell lymphoma: Moreover, combining ironomycin with Bcl2i, Bcl-xLi and Mcl1i, resulted in synergistic effects across all cell lines, confirming that ironomycin sensitizes MCL cells to Bcl2-family inhibitors (Figure S3B-D) that have been evaluated in relapsed MCL patients with promising results 42,43.